EGFR and nasopharyngeal carcinoma: Preliminary results from another phase 2 study combining MRG003 with the PD-1 inhibitor pucotenlimab demonstrated an ORR of 77.8% in 9 patients with EGFR-positive r/m NPC who progressed after first-line treatment of PD-1 plus platinum-based chemotherapy [57].